Akeso jumps as cancer drug helps patients live longer in China trial
BUZZ-Akeso jumps as cancer drug helps patients live longer in China trial ** Shares of China-based antibody drugs developer Akeso Inc 9926.HK jump 12.3% to HK$132.6, their highest since May 13
** An experimental drug developed by Akeso helped patients with advanced squamous non-small cell lung cancer live 15% longer than BeOne Medicines' 688235.SS immunotherapy Tevimbra, and cut the risk of death by more than one-third in a study presented at a medical meeting on Sunday
** Patients who received ivonescimab and chemotherapy lived an average of 27.9 months, compared with 23.7 months for those who received Tevimbra and chemotherapy, according to a brief summary of the study results
** The results are being presented at the American Society of Clinical Oncology meeting in Chicago on Sunday
** Shares of BeOne Medicines' 688235.SS slip 3% to 236.68 yuan, on track for the biggest one-day pct drop since May 18
** YTD, Akeso stock up 4.7%, while Hang Seng Biotech Index .HSBIO down 6.6%
(Reporting by Donny Kwok)
Recent news on Akeso
See all newsSummit drops as concerns over older patients cloud cancer trial data (updated)
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's
Akeso jumps as cancer drug helps patients live longer in China trial
Corrected: Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial (May 31)
J&T Global Express leads gain in newcomers to Hang Seng Index